SANTA CLARA, Calif., Jan. 21, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN) (“SI-BONE”), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that it has commenced an underwritten public offering of 4,300,000 shares of its common stock. In addition, SI-BONE expects to grant the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock on the same terms and conditions. Of the shares of common stock being offered, 1,809,947 shares are being offered by selling stockholders and 2,490,053 shares are being offered by SI-BONE. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Morgan Stanley and BofA Securities are acting as joint book-running managers.
A shelf registration statement relating to the shares being sold in this offering was filed with the U.S. Securities and Exchange Commission on December 26, 2019, and was declared effective on January 2, 2020. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. When available, electronic copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System.
This press release contains forward-looking statements, including statements relating to SI-BONE’s expectations regarding the proposed public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. SI-BONE cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions, the risk that the proposed public offering will not be consummated on the terms or in the amounts contemplated or otherwise, and the satisfaction of customary closing conditions related to the proposed public offering. Risks and uncertainties relating to SI-BONE and its business can be found in the “Risk Factors” section of SI-BONE’s Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 12, 2019, and in the preliminary prospectus contained in the registration statement related to the proposed public offering filed with the SEC on January 21, 2020. SI-BONE undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in SI-BONE’s expectations, except as required by law.
Lynn Lewis or Carrie Mendivil